Overview

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Capecitabine